drugset / Trial / NCT01695590
Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
To determine the maximum tolerated dose of, and response to, PRLX 93936 as treatment for patients with relapsed or relapsed/refractory multiple myeloma.
Timeline
- Start
- 2012-03
- Primary completion
- 2014-03
- Completion
- 2014-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PRLX 93936 | Unknown | — | Intravenous |